BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29195808)

  • 1. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.
    Amano H; Uchida H; Tanaka Y; Tainaka T; Mori M; Oguma E; Kishimoto H; Kawashima H; Arakawa Y; Hanada R; Koh K
    J Pediatr Surg; 2018 Sep; 53(9):1761-1765. PubMed ID: 29195808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
    Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
    Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
    Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes.
    Avanzini S; Pio L; Erminio G; Granata C; Holmes K; Gambart M; Buffa P; Castel V; Valteau Couanet D; Garaventa A; Pistorio A; Cecchetto G; Martucciello G; Mattioli G; Sarnacki S
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28440012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
    Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
    Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
    Paffenholz P; Pfister D; Heidenreich A
    Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study.
    Adkins ES; Sawin R; Gerbing RB; London WB; Matthay KK; Haase GM
    J Pediatr Surg; 2004 Jun; 39(6):931-6. PubMed ID: 15185228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma.
    Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
    Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
    Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S
    Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.
    Iehara T; Yagyu S; Tsuchiya K; Kuwahara Y; Miyachi M; Tajiri T; Sugimoto T; Sawada T; Hosoi H
    Jpn J Clin Oncol; 2016 Jul; 46(7):661-6. PubMed ID: 27207883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97.
    Hero B; Simon T; Spitz R; Ernestus K; Gnekow AK; Scheel-Walter HG; Schwabe D; Schilling FH; Benz-Bohm G; Berthold F
    J Clin Oncol; 2008 Mar; 26(9):1504-10. PubMed ID: 18349403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
    Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
    J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
    Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prognosis for infants with stage IV neuroblastoma.
    Kretschmar CS; Frantz CN; Rosen EM; Cassady JR; Levey R; Sallan SE
    J Clin Oncol; 1984 Jul; 2(7):799-803. PubMed ID: 6737020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China.
    Yao W; Li K; Dong KR; Zheng S; Xiao XM
    World J Pediatr; 2019 Apr; 15(2):148-152. PubMed ID: 30446974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology.
    Plantaz D; Rubie H; Michon J; Mechinaud F; Coze C; Chastagner P; Frappaz D; Gigaud M; Passagia JG; Hartmann O
    Cancer; 1996 Jul; 78(2):311-9. PubMed ID: 8674009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.